/EQ
EQ Stock - Equillium, Inc.
Healthcare|BiotechnologyNASDAQ
$1.15+6.48%
+$0.07 (+6.48%) • Dec 19
47
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.81
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).24
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.43
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-13.0%upside
Target: $1.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.14 – $1.16
TARGET (TP)$1.00
STOP LOSS$1.06
RISK/REWARD1:-1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.92
52W High$2.35
52W Low$0.27
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41.09M | $36.08M | $15.76M | N/A | N/A |
| Gross Profit | $41.09M | $36.08M | $15.76M | N/A | $-45,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | N/A | N/A |
| Operating Income | $-8,269,000 | $-14,522,000 | $-62,076,000 | $-37,786,000 | $-29,548,000 |
| Net Income | $-8,067,000 | $-13,335,000 | $-62,428,000 | $-38,980,000 | $-29,813,000 |
| Net Margin | -19.6% | -37.0% | -396.1% | N/A | N/A |
| EPS | $-0.23 | $-0.38 | $-3.19 | $-1.35 | $-1.46 |
Company Overview
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish0 Neutral/Bearish
Price Targets
$1
Average Target
↓ 13.0% Downside
Now
$1
Low
$1
Average
$1
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 28th 2025 | Leerink Partners | Downgrade | Market Perform | $1← $3 |
Earnings History & Surprises
EQBeat Rate
58%
Last 19 quarters
Avg Surprise
+46.3%
EPS vs Estimate
Beats / Misses
11/7
1 met exactly
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
+58.8%
$-0.07vs$-0.17
Q2 24
+52.9%
$-0.08vs$-0.17
Q3 24
+106.7%
$0.01vs$-0.15
Q4 24
+99.9%
$-0.00vs$-0.26
Q1 25
+27.3%
$-0.16vs$-0.22
Q2 25
-4.3%
$-0.24vs$-0.23
Q3 25
-14.3%
$-0.16vs$-0.14
Q4 25
+57.1%
$-0.06vs$-0.14
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.14 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.14 | $-0.06 | +57.1% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.14 | $-0.16 | -14.3% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.23 | $-0.24 | -4.3% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.22 | $-0.16 | +27.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.26 | $-0.00 | +99.9% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.15 | $0.01 | +106.7% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.17 | $-0.08 | +52.9% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-0.17 | $-0.07 | +58.8% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.19 | $-0.10 | +47.4% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.20 | $-0.11 | +45.0% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $0.02 | $0.08 | +407.6% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.39 | $-0.40 | -2.6% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.40 | $-0.41 | -2.5% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.36 | $-0.45 | -25.0% | ✗ MISS |
Q1 2022 | Mar 23, 2022 | $-0.34 | $-0.36 | -5.9% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.34 | $-0.35 | -2.9% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.31 | $-0.31 | 0.0% | = MET |
Q2 2021 | May 13, 2021 | $-0.34 | $-0.33 | +2.9% | ✓ BEAT |
Latest News
Equillium shares are trading higher after the company reported better-than-expected Q3 EPS. It also filed a mixed shelf offering of up to $250 million.
📈 PositiveBenzinga•Nov 14, 2025, 08:59 PM
Equillium Files For Mixed Shelf Of Up To $250M
➖ NeutralBenzinga•Nov 13, 2025, 09:57 PM
Equillium Q3 EPS $(0.06) Beats $(0.14) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:36 PM
Equillium Files Prospectus For $75M Share Offering
📉 NegativeBenzinga•Sep 19, 2025, 08:10 PM
Equillium Files For Offering Of Up To 52.63M Shares Of Common Stock By Selling Stockholders
📉 NegativeBenzinga•Sep 9, 2025, 09:04 PM
Frequently Asked Questions about EQ
What is EQ's current stock price?
Equillium, Inc. (EQ) is currently trading at $1.15 per share. The stock has moved +6.48% today.
What is the analyst price target for EQ?
The average analyst price target for EQ is $1.00, based on 1 analyst.
What sector is Equillium, Inc. in?
Equillium, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is EQ's market cap?
Equillium, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does EQ pay dividends?
No, Equillium, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCOEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
IPSC
Century Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
MDCX
Medicus Pharma Ltd. Common Stock
$1.69
Mkt Cap: $0.0B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
OSTX
OS Therapies Incorporated
$1.54
Mkt Cap: $0.1B
OTLK
Outlook Therapeutics, Inc.
$2.01
Mkt Cap: $0.1B
SPRB
Spruce Biosciences, Inc.
$78.74
Mkt Cap: $0.0B
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$1.41
Mkt Cap: $0.0B
Explore stocks similar to EQ for comparison